Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma

FASEB Journal

Volumn 27, Issue 9, 2013, Pages 3446-3454

  He, Wenjie ^a   Mazumder, Amitabha ^b   Wilder, Tuere ^a   Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Osteoblast differentiation; Osteoclast differentiation; Osteolytic bone disease

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ALKALINE PHOSPHATASE; BAY 60 6583; COMPLEMENTARY DNA; DIPYRIDAMOLE; MESSENGER RNA; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT COLONY STIMULATING FACTOR 1; ROLOFYLLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; BONE MARROW CELL; BONE METABOLISM; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MESENCHYMAL STEM CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

OSTEOBLAST DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; OSTEOLYTIC BONE DISEASE;

ACETAMIDES; ADENOSINE; AMINOPYRIDINES; ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CELLS, CULTURED; DIPYRIDAMOLE; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MULTIPLE MYELOMA; OSTEOCALCIN; OSTEOCLASTS; PURINERGIC P1 RECEPTOR AGONISTS; PURINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XANTHINES;

EID: 84883406185     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-231233     Document Type: Article

References (45)

1. Roodman, G. D. (2004) Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664
2. Saad, F., Lipton, A., Cook, R., Chen, Y. M., Smith, M., and Coleman, R. (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110, 1860-1867
3. Sonmez, M., Akagun, T., Topbas, M., Cobanoglu, U., Sonmez, B., Yilmaz, M., Ovali, E., and Omay, S. B. (2008) Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J. Exp. Clin. Cancer Res. 27, 11
4. Melton, L. J., 3rd, Kyle, R. A., Achenbach, S. J., Oberg, A. L., and Rajkumar, S. V. (2005) Fracture risk with multiple myeloma: a population-based study. J. Bone Miner. Res. 20, 487-493
5. Valentin-Opran, A., Charhon, S. A., Meunier, P. J., Edouard, C. M., and Arlot, M. E. (1982) Quantitative histology of myeloma- induced bone changes. Br. J. Haematol. 52, 601-610
6. Taube, T., Beneton, M. N., McCloskey, E. V., Rogers, S., and Greaves, M., Kanis, J. A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur. J. Haematol. 49, 192-198
7. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., and Alexandre, C. (1989) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. 7, 1909-1914
8. Sati, H. I., Greaves, M., Apperley, J. F., Russell, R. G., and Croucher, P. I. (1999) Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br. J. Haematol. 104, 350-357
9. Oyajobi, B. O., Franchin, G., Williams, P. J., Pulkrabek, D., Gupta, A., Munoz, S., Grubbs, B., Zhao, M., Chen, D., Sherry, B., and Mundy, G. R. (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102, 311-319
10. Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G., and Anderson, K. C. (2006) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42, 1564-1573
11. Hideshima, T., Chauhan, D., Podar, K., Schlossman, R. L., and Richardson, P., Anderson, K. C. (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol. 28, 607-612
12. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., and Shaughnessy, J. D., Jr. 2003. The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494
13. Qiang, Y. W., Chen, Y., Stephens, O., Brown, N., Chen, B., Epstein, J., Barlogie, B., and Shaughnessy, J. D., Jr. 2008. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112, 196-207
14. Mediero, A., Frenkel, S. R., Wilder, T., He, W., Mazumder, A., and Cronstein, B. N. 2012. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci. Transl. Med. 4, 135ra65
15. Mediero, A., Kara, F. M., Wilder, T., and Cronstein, B. N. (2012) Adenosine A(2A) receptor ligation inhibits osteoclast formation. Am. J. Pathol. 180, 775-786
16. He, W., and Cronstein, B. N. (2012) Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. Purinergic Signal. 8, 327-337
17. Kara, F. M., Chitu, V., Sloane, J., Axelrod, M., Fredholm, B. B., Stanley, E. R., and Cronstein, B. N. (2010) Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J. 24, 2325-2333
18. Kara, F. M., Doty, S. B., Boskey, A., Goldring, S., Zaidi, M., Fredholm, B. B., and Cronstein, B. N. (2010) Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum. 62, 534-541
19. Carroll, S. H., Wigner, N. A., Kulkarni, N., Johnston-Cox, H., Gerstenfeld, L. C., and Ravid, K. (2012) A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J. Biol. Chem. 287, 15718-15727
20. Costa, M. A., Barbosa, A., Neto, E., Sa-e-Sousa, A., Freitas, R., Neves, J. M., Magalhaes-Cardoso, T., Ferreirinha, F., and Correia- de-Sa, P. (2011) On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells. J. Cell. Physiol. 226, 1353-1366
21. Gharibi, B., Abraham, A. A., Ham, J., and Evans, B. A. (2011) Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. J. Bone Miner. Res. 26, 2112-2124
22. Takedachi, M., Oohara, H., Smith, B. J., Iyama, M., Kobashi, M., Maeda, K., Long, C. L., Humphrey, M. B., Stoecker, B. J., Toyosawa, S., Thompson, L. F., and Murakami, S. (2012) CD73-generated adenosine promotes osteoblast differentiation. J. Cell. Physiol. 227, 2622-2631
23. Subbarao, K., Rucinski, B., Rausch, M. A., Schmid, K., and Niewiarowski, S. (1977) Binding of dipyridamole to human platelets and to alpha1 acid glycoprotein and its significance for the inhibition of adenosine uptake. J. Clin. Invest. 60, 936-943
24. Pellegatti, P., Falzoni, S., Donvito, G., Lemaire, I., and Di Virgilio, F. (2011) P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J. 25, 1264-1274
25. Young, J. D., Yao, S. Y., Sun, L., Cass, C. E., and Baldwin, S. A. (2008) Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 38, 995-1021
26. King, A. E., Ackley, M. A., Cass, C. E., Young, J. D., and Baldwin, S. A. (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol. Sci. 27, 416-425
27. Grenz, A., Bauerle, J. D., Dalton, J. H., Ridyard, D., Badulak, A., Tak, E., McNamee, E. N., Clambey, E., Moldovan, R., Reyes, G., Klawitter, J., Ambler, K., Magee, K., Christians, U., Brodsky, K. S., Ravid, K., Choi, D. S., Wen, J., Lukashev, D., Blackburn, M. R., Osswald, H., Coe, I. R., Nurnberg, B., Haase, V. H., Xia, Y., Sitkovsky, M., and Eltzschig, H. K. (2012) Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J. Clin. Invest. 122, 693-710
28. Morote-Garcia, J. C., Rosenberger, P., Nivillac, N. M., Coe, I. R., and Eltzschig, H. K. (2009) Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 136, 607-618
29. Eckle, T., Hughes, K., Ehrentraut, H., Brodsky, K. S., Rosenberger, P., Choi, D. S., Ravid, K., Weng, T., Xia, Y., Blackburn, M. R., and Eltzschig, H. K. 2013. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. [E-pub ahead of print] FASEB J. doi: 10.1096/fj.13-228551
30. Warraich, S., Bone, D. B., Quinonez, D., Ii, H., Choi, D. S., Holdsworth, D. W., Drangova, M., Dixon, S. J., Seguin, C. A., and Hammond, J. R. (2013) Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. J. Bone Miner. Res. 28, 1135-1149
31. Eltzschig, H. K., Sitkovsky, M. V., and Robson, S. C. (2012) Purinergic signaling during inflammation. N. Engl. J. Med. 367, 2322-2333
32. Eckle, T., Hartmann, K., Bonney, S., Reithel, S., Mittelbronn, M., Walker, L. A., Lowes, B. D., Han, J., Borchers, C. H., Buttrick, P. M., Kominsky, D. J., Colgan, S. P., and Eltzschig, H. K. (2012) Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat. Med. 18, 774-782
33. Khoa, N. D., Montesinos, M. C., Reiss, A. B., Delano, D., Awadallah, N., and Cronstein, B. N. (2001) Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J. Immunol. 167, 4026- 4032
34. Nguyen, D. K., Montesinos, M. C., Williams, A. J., Kelly, M., and Cronstein, B. N. (2003) Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J. Immunol. 171, 3991-3998
35. Barille, S., Collette, M., Bataille, R., and Amiot, M. (1995) Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 86, 3151-3159
36. Lust, J. A., and Donovan, K. A. (1999) The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. N. Am. 13, 1117-1125
37. Lai, F. P., Cole-Sinclair, M., Cheng, W. J., Quinn, J. M., Gillespie, M. T., Sentry, J. W., and Schneider, H. G. (2004) Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br. J. Haematol. 126, 192-201
38. Goranova-Marinova, V., Goranov, S., Pavlov, P., and Tzvetkova, T. (2007) Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma: clinical correlations. Haematologica 92, 1000-1001
39. Hashimoto, T., Abe, M., Oshima, T., Shibata, H., Ozaki, S., Inoue, D., and Matsumoto, T. (2004) Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br. J. Haematol. 125, 38-41
40. Uneda, S., Hata, H., Matsuno, F., Harada, N., Mitsuya, Y., Kawano, F., and Mitsuya, H. (2003) Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br. J. Haematol. 120, 53-55
41. Filella, X., Blade, J., Guillermo, A. L., Molina, R., Rozman, C., and Ballesta, A. M. (1996) Cytokines (IL-6, TNF-alpha, IL- 1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prev. 20, 52-56
42. Evans, B. A., Elford, C., Pexa, A., Francis, K., Hughes, A. C., Deussen, A., and Ham, J. (2006) Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J. Bone Miner. Res. 21, 228-236
43. Szabo, C., Scott, G. S., Virag, L., Egnaczyk, G., Salzman, A. L., Shanley, T. P., and Hasko, G. (1998) Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen- induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125, 379-387
44. Hasko, G., Kuhel, D. G., Chen, J. F., Schwarzschild, M. A., Deitch, E. A., Mabley, J. G., Marton, A., and Szabo, C. (2000) Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14, 2065-2074
45. Gharibi, B., Abraham, A. A., Ham, J., and Evans, B. A. (2012) Contrasting effects of A1 and A2b adenosine receptors on adipogenesis. Int. J. Obes. (Lond.) 36, 397-406